TVARDI THERAPEUTICS
Tvardi Therapeutics they are focused on the development of orally delivered, small molecule inhibitors of STAT3. They provide medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases.
TVARDI THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Service Industry
Founded:
2017-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.tvarditherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
832-413-1362
Total Funding:
81.42 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Maps LetsEncrypt SSL By Default
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Koya Medical
Koya Medical is a transformative healthcare company developing breakthrough treatments for lymphedema and venous diseases.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Current Advisors List
Current Employees Featured
Founder
Investors List
683 CAPITAL
683 CAPITAL investment in Series B - Tvardi Therapeutics
Slate Path Capital
Slate Path Capital investment in Series B - Tvardi Therapeutics
Sporos Bioventures
Sporos Bioventures investment in Series B - Tvardi Therapeutics
ArrowMark Partners
ArrowMark Partners investment in Series B - Tvardi Therapeutics
Piedmont Capital Investments
Piedmont Capital Investments investment in Series B - Tvardi Therapeutics
THE CATALYTIC IMPACT FOUNDATION (CIF)
THE CATALYTIC IMPACT FOUNDATION (CIF) investment in Series B - Tvardi Therapeutics
Official Site Inspections
http://www.tvarditherapeutics.com Semrush global rank: 16.19 M Semrush visits lastest month: 1
- Host name: secure.depinhodesign.com
- IP address: 104.247.77.142
- Location: Los Angeles United States
- Latitude: 33.956
- Longitude: -118.3887
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90045
More informations about "Tvardi Therapeutics"
Company Overview - Tvardi Therapeutics
Tvardi is focused on the development of inhibitors of STAT3, a key signaling molecule positioned at the intersection of many pathways controlling gene networks integral to the survival and immune sequestration of cancer cells as …See details»
Leadership Team - Tvardi Therapeutics
Kari Anne Rowland, M.S. brings twenty years of industry and life sciences experience mostly dedicated to clinical stage development of biological and small molecule therapeutics across …See details»
Tvardi Therapeutics - LinkedIn
Tvardi Therapeutics | 2,053 followers on LinkedIn. Breakthrough Medicines for Cancer, Chronic Inflammation & Fibrosis | Tvardi is a privately held, clinical-stage, biopharmaceutical company ...See details»
Tvardi Therapeutics - Crunchbase Company Profile & Funding
Tvardi Therapeutics they are focused on the development of orally delivered, small molecule inhibitors of STAT3. They provide medicines for diverse cancers, chronic inflammatory …See details»
Tvardi Therapeutics Company Profile 2024: Valuation, …
Tvardi Therapeutics General Information Description. Operator of a clinical-stage biopharmaceutical company intended to develop small molecule inhibitors of STAT3. The company develops the key regulatory protein positioned at the …See details»
Tvardi Therapeutics - VentureRadar
Website: https://tvarditherapeutics.com. Develops breakthrough medicines for diverse cancers, chronic inflammatory diseases, and fibrotic diseases through clinical stage, private …See details»
Tvardi Therapeutics - Overview, News & Similar companies
Feb 29, 2024 Tvardi Therapeutics to Participate at the Cowen 44th Annual Health Care Conference HOUSTON--(BUSINESS WIRE)-- #HCC--Tvardi Therapeutics, Inc. (“Tvardi”), a …See details»
Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation …
May 26, 2022 Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, todaySee details»
Tvardi Raises $74M to Advance STAT3 Inhibitors for Cancer, Fibrosis
Jun 23, 2021 Tvardi Therapeutics Inc., a company targeting a protein essential to cancer cells’ survival and immune evasion, closed a $74 million series B financing.See details»
Tvardi snags $74M to weed the tumor garden with …
Jun 23, 2021 Tvardi Therapeutics, an upstart biotech from the brains of MD Anderson Cancer Center leaders, has raised $74 million to prep for a phase 2 trial of an oral, small-molecule inhibitor signal ...See details»
Tvardi Therapeutics - Craft
Tvardi Therapeutics is a biotechnology company developing medicines for the treatment of cancer, chronic inflammation, and fibrosis. It specializes in producing inhibitors of STAT3, a …See details»
Tvardi Therapeutics Announces Presentation of Data from the …
May 25, 2023 HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) will publicly present, for the first time, clinical results from the Phase 1 study of TTI-101, a STAT3 inhibitor, …See details»
Tvardi Therapeutics to Present at the Morgan Stanley 20
Sep 8, 2022 Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, annouSee details»
Contact - Tvardi Therapeutics
Please complete the form for general or media inquiries or if you are interested in learning more about Tvardi Therapeutics. A company representative will respond at our earliest convenience.See details»
Our Science - Tvardi Therapeutics
The pro-proliferative and pro-survival activity of STAT3 is also a central mediator for chronic inflammation and fibrosis. For example, a single allelic knockout of STAT3 inhibits fibrotic …See details»
Tvardi Therapeutics Announces First Patients Dosed in Phase 2 …
Feb 23, 2023 Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that tSee details»
Tvardi Therapeutics Announces First Patients Dosed in its
Jun 22, 2023 HOUSTON--(BUSINESS WIRE)-- Tvardi Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, …See details»
Tvardi's TTI-101 Receives $5 Million in Funding to Support Clinical ...
Jul 24, 2020 FOR IMMEDIATE RELEASE. Houston, TX. July 24, 2020 – Tvardi Therapeutics Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the …See details»
Tvardi Therapeutics Raises $74 Million in Series B Financing to …
Jun 23, 2021 HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 …See details»